Ascletis submits two obesity-drug IND applications to US FDA for ASC36, ASC36_35 FDC injections

• Ascletis filed two U.S. FDA IND applications for obesity candidates ASC36 once-monthly injection and ASC36_35 fixed-dose co-formulation once-monthly injection.
• ASC36_35 targets amylin receptor, GLP-1R, GIPR; ASC36 targets amylin receptor with dosing potential extending to once-quarterly.
• IND submissions follow recent U.S. FDA IND clearance to start a Phase 1 trial for ASC35 as a once-monthly obesity treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260706-12233090), on July 06, 2026, and is solely responsible for the information contained therein.